One architecture for a wide range
of markets and applications

The energy required for current and future computing needs of high performance and LLM processing is skyrocketing in data centers. At the same time, reliability and security is a critical concern given the large number of processing systems manufactured in advanced nodes. Ceremorphic’s ground-up architecture built with hierarchical processing systems including hybrid quantum processors features low power consumption and industry-best-reliability technology to ensure uninterrupted application execution.

The future of drug discovery lies in personalized medicine, free from side effects. This ambitious goal demands a quantum leap in technology at every stage of the current drug discovery pipeline. The pharmaceutical industry has faced significant challenges in drug development, primarily due to inefficiencies in the methodology, leading to increased costs, extended development times, and poor efficacy. The alarming statistics, with over 90% drug failures at Clinical Phase II and a mere small number of new drugs approved annually by FDA, underscore the urgency of the situation and necessitate a fundamentally new approach in the early stages of drug design and validation.

Ceremorphic has developed an innovative architecture based on its proprietary hybrid quantum and AI technology to predict outcomes more accurately early on, significantly enhancing the overall R&D efficiency of the process. The core principles of this approach revolve around generating sufficient relevant data to construct meaningful foundation models. This data is generated through in-silico emulation technology, harnessing the power of quantum chip technologies. This groundbreaking innovation has the potential to revolutionize drug discovery, not only accelerating the development of new drugs but also paving the way for the realization of personalized medicine in the near future!